Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points

Current Opinion in Lipidology

Volumn 7, Issue 6, 1996, Pages 389-397

  Kinlay, Scott ^a   Selwyn, Andrew R ^a   Delagrange, Danielle ^a   Creager, Mark A ^a   Libby, Peter ^a   Ganz, Peter ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; REVASCULARIZATION; REVIEW; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASOMOTOR REFLEX;

THROMBUS;

EID: 0030499777     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199612000-00009     Document Type: Review

References (104)

1. ••].
2. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering therapy in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
3. ••] are the recent large randomized controlled trials which demonstrated that lipid-lowering with HMG CoA reductase inhibitors reduces coronary events and overall mortality in individuals at high risk of coronary artery disease.
4. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. N Engl J Med 1995, 332:512-521.
5. Wissler RW, Vesselinovitch D: Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animals models. Am J Cardiol 1990, 65:33F-40F.
6. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
7. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992, 339:563-569.
8. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashian-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI: Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993, 119:969-976.
9. Haskell WL, Laderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM: Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994, 89:975-990.
10. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994, 344:1182-1186.
11. MAAS Investigators: Effect of simvastatin on coronary atheroma. The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638.
12. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959-968.
13. Jukema JW, Brauschke AVG, van Boven AJ, Reiber JH, Bal ET, Zwinderman A, Jansen H, Boerma GJ, van Rappard FM, Lie KI: Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
14. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-1): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995, 26:1133-1139.
15. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995, 76:86C-92C.
16. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461-1467.
17. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ et al: Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984, 69:313-324.
18. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1371-1375.
19. Zarins CK, Weisenberg E, Kolettis G, Stankunavicius R, Glagov: Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. J Vasc Surg 1988, 7:386-394.
20. Stiel GM, Stiel LSG, Schofer J, Donath K, Mathey DG: Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic assessment of coronary artery disease. Circulation 1989, 80:1603-1609.
21. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein PS: Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994, 271:289-294.
22. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland M, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90:1679-1687.
23. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, lipid and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995, 75:455-459.
24. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988, 9:1317-1323.
25. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borneo S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988, 12:56-62.
26. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988, 78:1157-1166.
27. Nobuyoshi M, Tanaka M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Kim K, Shindo T, Kimura K: Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol 1991, 18:904-910.
28. Giroud D, Li JM, Urban P, Meier B, Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992, 69:729-732.
29. Davies MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990, 82:38-46.
30. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle content. Br Heart J 1993, 69:377-381.
31. Falk E: Why do plaques rupture? Circulation 1992, 86(suppl III):30-42.
32. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657-671.
33. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 2844-2850. A review of the evidence of how inflammatory change within the plaque may relate to the vulnerability of the plaque to rupture.
34. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991, 88:8154-8158.
35. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
36. Galis ZS, Muszynski, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994, 75:181-189.
37. Galis ZS, Sukhova G, Kranzhofer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995, 92:402-406.
38. Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980.
39. Nikkari ST, O'Brien KD, Ferguson M, Halsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995, 92:1393-1398.
40. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92:1565-1569.
41. Amento EP, Ehsani N, Palmer H, Libby P: Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991, 11:1223-1230.
42. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
43. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995, 76:24C-33C.
44. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989, 86:2839-2843.
45. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J 1995, 16(suppl E):6-12.
46. Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980, 302:6-10.
47. DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M: Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 1986, 6:203-211.
48. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92:3172-3177.
49. Badimon JJ, Badimon L, Turitto VT, Fuster V: Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. Arterioscler Thromb 1991, 11:395-402.
50. Padgett RC, Heistad DD, Mugge A, Armstrong ML, Piegors DJ, Lopez JAG: Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res 1992, 70:423-429.
51. Armstrong ML, Warner E, Connor W: Regression of coronary atheromatosis in rhesus monkeys. Circ Res 1970, 27:59-67.
52. Clarkson TB, Bond MG, Bullock BC, Marzetta CA: A study of atherosclerosis regression in Macaca mulatta. Exp Mol Pathol 1981, 34:345-368.
53. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK: Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest 1984, 73:1590-1605.
54. Small DM: Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis 1988, 8:103-129.
55. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT: Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994, 14:230-134.
56. Nishimura RA, Edwards WD, Warnes CA, Reeder GS, Holmes DR Jr, Tajik AJ, Yock PG: Intravascular ultrasound imaging: in vitro validation and pathologic correlation. J Am Coll Cardiol 1990, 16:145-154.
57. Hausmann D, Lundkvist AJ s, Friedrich GJ, Mullen WL, Fitzgerald PJ, Yock PG: Intracoronary ultrasound imaging: intraobserver and interobserver variability of morphometric measurements. Am Heart J 1994, 128:674-680.
58. Losordo DW, Rosenfield K, Kaufman J, Pieczek A, Isner JM: Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation 1994, 89:2570-2577.
59. Skinner MP, Yuan C, Mitsumori L, Hayes CE, Raines EW, Nelson JA, Ross R: Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nature Med 1995, 1:69-73.
60. McConnell MV, Ganz P, Lee RT, Selwyn AP, Libby P: Imaging atherosclerosis: lesion vs. lumen. In Cardiovascular imaging. Edited by Reiber JHC, van der Wall EE. The Netherlands: Kluwer Academic Publishers; 1996:93-107.
61. Toussaint JF, Southern JF, Fuster V, Kantor HL: T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol 1995, 15:1533-1542.
62. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
63. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
64. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
65. Myers PR, Guerra R, Bates JN, Harrison DG. The vasorelaxant properties of the endothelium-derived relaxing factor more closely resembles S-nitrosocysteine than nitric oxide. Nature 1990, 345:161-163.
66. Lamas S, Marsden PA, Li GK, Tempst P, Michel T: Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992, 89:6348-6352.
67. Meredith IT, Yeung AC, Weidinger FF, Anderson TJ, Uehata A, Ryan TJ, Jr, Selwyn AP, Ganz P: Role of impaired endothelium-dependent vasodilation in the ischemic manifestations of coronary artery disease. Circulation 1993, 87(suppl V):V56-V66.
68. Meredith IT, Anderson TJ, Uehata A, Yeung AC, Selwyn AP, Ganz P: The role of the endothelium in ischemic coronary syndromes. Am J Cardiol 1993, 72:27C-32C.
69. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
70. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A: Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993, 88:43-54.
71. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III: Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995, 95:1747-1755.
72. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546-1551.
73. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P: The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990, 81:491-497.
74. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991, 83:391-401.
75. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A: Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993, 91:29-37.
76. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III: Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995, 92:320-326.
77. Dyce MC, Anderson TJ, Yeung AC, Ganz P, Lieberman EH, Gerhard MD, Selwyn AP, Meredith IT: Indices of LDL particle size closely relate to endothelial function [Abstract]. Circulation 1993, 88(1):466.
78. Anderson TJ, Meredith IT, Yeung AC, Charbonneau F, Selwyn AP, Ganz P: Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996, 93:1647-1650. This study demonstrated that LDL susceptability to oxidation is highly correlated to the impairment of coronary endothelial vasomotor function.
79. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE: Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991, 68:1425-1430.
80. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H: Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994, 89:2525-2532.
81. Cox DA, Cohen ML: Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev 1996, 48:3-19. A review of the studies that have determined the mechanisms by which oxidized LDL may impair endothelial function.
82. Liao JK, Shin WS, Lee WY, Clark SL: Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995, 270:319-324.
83. i2 submit expression by oxidized low-density lipoprotein. J Clin Invest 1995, 95:1457-1463.
84. Leung WH, Lau CP, Wong CK: Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemia patients. Lancet 1993, 341:1496-1500.
85. ••].
86. ••] were the first randomized controlled trials to demonstrate that lowering LDL and oxidized LDL can improve coronary endothelial vasomotor function.
87. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP: Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986, 73:865-876.
88. Gordon JB, Ganz P, Nabel EG, Zebede J, Mudge GH, Alexander RW, Selwyn AP: Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J Clin Invest 1989, 83:1946-1952.
89. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP: The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1989, 325:1551-1556.
90. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP: Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold presser test. Circulation 1988, 77:43-52.
91. Nabel EG, Selwyn AP, Ganz P: Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990, 81:850-859.
92. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP: Impairment of flow-mediated coronary dilation by atherosclerosis in man. Circulation 1989, 80:458-465.
93. Nabel EG, Selwyn AP, Ganz P: Large coronary arteries in humans are responsive to changes in blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990, 16:349-356.
94. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP: Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992, 85:1390-1397.
95. Seiler C, Suter TM, Hess OM: Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995, 26:1615-1622.
96. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
97. Andrews TC, Barry J, Naimi C, Allred E, Ganz P, Selwyn AP: The effect of LDL cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1996 (in press).
98. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange I, Creager MA, Selwyn AP, Ganz P: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995, 75:71B-74B.
99. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP: Close relationship of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995, 26:1235-1241. The authors of this study demonstrated the systemic nature of endothelial dysfunction. Endothelial dysfunction in the coronary tree was correlated with endothelial dysfunction in the brachial artery.
100. Pohl U, Holtz J, Busse R, Bassenge E: Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986, 8:37-44.
101. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, Creager MA: Flow mediated vasodilation of the brachial artery is impaired in patients < 40 years of age with coronary artery disease. Am J Cardiol (in press).
102. Celemajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE:. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
103. Okumura K, Yasue H, Matsuyama K, Ogawa H, Moricami Y, Obata K, Sakaino N: Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992, 19:752-758.
104. Bogaty P, Hackert D, Davies G, Maseri A: Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994, 90:5-11.